A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis loco regionally advanced HPV-associated oropharyngeal squamous cell carcinoma

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Participating Centres

Final Accrual

189

Current Accrual

Closing Date of Accrual

7th June 2018

Trial Chairperson

Prof Danny Rischin and A/Prof June Corry

Trial Contact

anetta.matera@petermac.org

Clinical Trial Registration

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a